Suchergebnisse - "Lommatzsch, Marek"

PubPharm (29)

1

Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort

enthalten in: The journal of allergy and clinical immunology. In practice | 2023

von Milger, K. | Suhling, H. | Skowasch, D. | +13

CommentIn: J Allergy Clin Immunol Pract. 2023 Sep;11(9):2713-2714. - PMID 37684073

2

Dupilumab treatment increases transitional B cells in severe asthma

enthalten in: Allergy | 2023

von Lommatzsch, M. | Dost, M. | Jaishankar, N. | +4

3

Safety of combining biologics in severe asthma : Asthma-related and unrelated combinations

enthalten in: Allergy | 2022

von Lommatzsch, M. | Suhling, H. | Korn, S. | +7

4

Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease : results from COSYCONET

enthalten in: Scientific reports | 2022

von Trudzinski, F. | Jörres, R. | Alter, P. | +52

5

Oral corticosteroid prescription for asthma by general practitioners : A three-year analysis in Germany

enthalten in: Respiratory medicine | 2021

von Lommatzsch, M. | Sauerbeck, I. | Wilmer, C. | +1

6

Benralizumab strongly reduces blood basophils in severe eosinophilic asthma

enthalten in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology | 2020

von Lommatzsch, M. | Marchewski, H. | Schwefel, G. | +3

7

COVID-19 in a patient with severe asthma treated with Omalizumab

enthalten in: Allergy | 2020

von Lommatzsch, M. | Stoll, P. | Virchow, J.

8

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma : 1-year results from the BORA phase 3 extension trial

enthalten in: The Lancet. Respiratory medicine | 2019

von Busse, W. | Bleecker, E. | FitzGerald, J. | +107

CommentIn: Lancet Respir Med. 2019 Jan;7(1):5-6. - PMID 30416084

9

Addressing unmet needs in understanding asthma mechanisms : From the European Asthma Research and Innovation Partnership (EARIP) Work Package (WP)2 collaborators

enthalten in: The European respiratory journal | 2017

von Edwards, M. | Saglani, S. | Schwarze, J. | +22

10

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA) : a randomised, double-blind, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2016

von FitzGerald, J. | Bleecker, E. | Nair, P. | +12

CommentIn: Lancet. 2016 Oct 29;388(10056):2059-2060. - PMID 27609409